All the key sources confirmed. Here is the complete plain text TB-500 overview ready to copy and paste.
TB-500 — Research Overview
Chemical Name: Ac-Lys-Lys-Thr-Glu-Thr-Gln (acetylated heptapeptide; Ac-LKKTETQ) Also Known As: TB-500; the active actin-binding fragment of Thymosin Beta-4 (Tβ4) Sequence: LKKTETQ (single-letter amino acid notation); N-terminally acetylated in the research compound form Molecular Weight of TB-500 fragment: Approximately 796 Da Parent Protein: Thymosin Beta-4 (Tβ4) — a naturally occurring 43-amino acid peptide with a molecular weight of approximately 4,963 Da, first purified from calf thymus tissue by Allan Goldstein and colleagues at the National Institutes of Health in 1981. Tβ4 is one of the most abundant intracellular peptides in mammalian cells, present in high concentrations in virtually all nucleated cell types, with particularly high concentrations in platelets, white blood cells, plasma, and wound fluid. It is encoded by the TMSB4X gene and represents the most abundant and biologically active member of the beta-thymosin family. Relationship between Tβ4 and TB-500: Thymosin Beta-4 (43 amino acids, full-length endogenous peptide) is the naturally occurring parent molecule. TB-500 refers specifically to the synthetic research peptide corresponding to the active actin-binding domain region (the heptapeptide LKKTETQ, approximately residues 17-23 of the full sequence), N-terminally acetylated. The LKKTETQ fragment is the pharmacophore — the minimal active sequence responsible for actin sequestration activity and much of Tβ4’s biological activity in repair models. A key 2003 study directly demonstrated that the seven-amino acid synthetic peptide LKKTETQ promoted wound repair in aged mice comparable to that observed with the full 43-amino acid parent molecule (Philp et al., 2003, PMID 12581423). This is the foundational evidence establishing TB-500’s validity as a research tool independent of full Tβ4. TB-500 and full Tβ4 are not the same compound and should not be used interchangeably in research reporting — all human clinical data (RGN-259, RGN-352) was generated with full Tβ4, not with the TB-500 fragment. WADA Status: Thymosin Beta-4 (and by extension the TB-500 fragment) is prohibited in equine sports and has been detected in anti-doping testing in racehorses. WADA assessment for human athlete testing is ongoing — researchers in sports science contexts should verify current WADA categorization. FDA Status: Not approved for any human or veterinary therapeutic indication. Full Tβ4 clinical development by RegeneRx Pharmaceuticals under formulation designations RGN-259 (ophthalmic), RGN-352 (cardiac), and RGN-137 (dermal) has been conducted in Phase 2 and Phase 3 trials; no FDA approval has been granted as of this compilation. Category: Synthetic actin-sequestering peptide fragment / G-actin binding domain heptapeptide / cytoskeletal dynamics research tool / tissue repair and wound healing research peptide / cardiac progenitor cell biology tool / angiogenesis research compound
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is TB-500?
TB-500 is a synthetic heptapeptide corresponding to the active actin-binding domain of Thymosin Beta-4 — the most abundant intracellular peptide in mammalian cells and one of the most biologically multifunctional regulatory peptides identified in the thymus and circulating tissues. Thymosin Beta-4’s primary molecular role is sequestration of G-actin (globular, monomeric actin): it binds actin monomers with high affinity, preventing their premature polymerization while maintaining a readily mobilizable pool of actin available for rapid cytoskeletal reorganization whenever cells receive signals to migrate, divide, or remodel. Because actin dynamics are foundational to virtually every process that requires cells to move — wound healing, angiogenesis, tissue repair, inflammation resolution, cardiac regeneration — Tβ4 and its active fragment TB-500 sit at the mechanistic center of regenerative biology.
The discovery of TB-500’s significance as an independent active fragment, rather than simply a degradation product of Tβ4, emerged from work by Philp et al. at the National Institute of Dental and Craniofacial Research at NIH (2003), which directly tested the synthetic LKKTETQ heptapeptide alongside full Tβ4 in impaired wound healing models. The heptapeptide produced repair activity in aged mice comparable to the full 43-amino acid molecule — establishing the pharmacophoric sufficiency of the LKKTETQ domain and validating the rationale for using TB-500 as a tractable research tool for studying Tβ4 biology without the cost and complexity of manufacturing the full-length peptide.
Tβ4’s biology extends well beyond actin sequestration: it activates integrin-linked kinase (ILK) and downstream Akt survival signaling, upregulates VEGF expression and drives angiogenesis, modulates NF-kB-mediated inflammatory signaling, promotes MMP production for extracellular matrix remodeling, activates dormant cardiac epicardial progenitor cells, and inhibits apoptosis through PINCH/ILK/Akt complex formation. The TB-500 fragment reproduces many of these effects through the cytoskeletal dynamics changes initiated by its G-actin binding activity, with some effects — particularly the ILK cardiac signaling — attributed to domains within or near the actin-binding region.
Thymosin Beta-4 — The Full Molecule Context
Tβ4 was first isolated in 1981 from calf thymus tissue (hence the thymus naming, though it is now understood to be nearly ubiquitous). Its original identification as a thymus-derived protein led to classification in the thymosin family — which also includes Thymosin Alpha-1. Despite sharing the “thymosin” name, Thymosin Alpha-1 and Thymosin Beta-4/TB-500 are pharmacologically unrelated compounds: Thymosin Alpha-1 is a 28-amino acid immune-regulatory peptide acting through toll-like receptors and T-cell maturation pathways; Tβ4/TB-500 is an actin-binding, cytoskeletal dynamics peptide acting through cell migration and repair biology. The shared name reflects historical isolation from thymic tissue, not mechanistic similarity.
Tβ4 is unusual in its abundance: it sequesters approximately 40-50% of the total G-actin pool in most cell types under resting conditions, making it the principal regulator of actin polymerization homeostasis in eukaryotic cells. When injury occurs — whether cutaneous, cardiac, neural, or ocular — Tβ4 is rapidly released from platelets and immune cells arriving at the wound site, reaching concentrations of approximately 13 micrograms per milliliter in human wound fluid. This high local concentration drives the cell migration, angiogenesis, and matrix remodeling programs that constitute the repair cascade. Exogenous administration of Tβ4 or TB-500 is hypothesized to amplify or extend this endogenous repair signal.
Mechanism of Action
G-actin sequestration and cytoskeletal dynamics regulation: The LKKTETQ core sequence of TB-500 binds G-actin monomers with high affinity (Kd approximately 0.5-0.7 micromolar). This sequestration maintains a large pool of actin in a polymerization-ready but unincorporated state. When cells receive migration signals — from growth factors, inflammatory mediators, or mechanical injury cues — this sequestered actin is released and rapidly channeled to the cell’s leading edge, where it polymerizes into lamellipodia and filopodia, the membrane protrusions that drive directed cell movement. TB-500 thus functions as a regulatory reservoir that makes cell migration faster, more efficient, and more responsive to directional signals than it would be without the sequestered actin pool.
This actin-buffering role is directly relevant to wound healing because the rate of wound closure depends on how quickly keratinocytes, fibroblasts, and endothelial cells can migrate into and across the wound bed. Tβ4/TB-500’s enhancement of cell migratory capacity accelerates each of these cell types’ wound response, compressing the healing timeline.
ILK activation and Akt survival signaling: Tβ4 activates integrin-linked kinase (ILK) through formation of a ternary complex involving Tβ4, PINCH (a scaffold protein that bridges ILK to signaling complexes), and ILK itself. ILK activation phosphorylates and activates Akt (protein kinase B) — the central pro-survival kinase that inhibits apoptosis, promotes cell growth, and supports cell migration. This ILK/Akt pathway was the mechanistic finding of the landmark Bock-Marquette et al. 2004 Nature paper, which established that Tβ4-mediated ILK activation promotes cardiac cell migration, survival, and cardiac repair after myocardial infarction. The ILK pathway explains why Tβ4’s effects extend beyond simple actin modulation to include cell survival under the ischemic and oxidative stress conditions that characterize injury sites.
VEGF upregulation and angiogenesis: Tβ4 upregulates VEGF (vascular endothelial growth factor) expression and directly promotes endothelial cell migration — the two cellular events required for angiogenesis. New blood vessel formation is rate-limiting for repair in many tissues, particularly those with poor intrinsic vascularity (tendons, ligaments, cartilage) or ischemic conditions (infarction zones, chronic wounds). Tβ4/TB-500’s angiogenic activity provides the blood supply that sustains ongoing cellular repair activity at the injury site.
NF-kB modulation and anti-inflammatory effects: Tβ4 inhibits NF-kB activation — the central transcription factor driving pro-inflammatory gene expression — through interactions with PINCH-1 and ILK that redirect the signaling complex away from NF-kB activation. This anti-inflammatory effect reduces chronic inflammatory burden at wound sites, which is important because sustained inflammation impairs rather than promotes healing. Tβ4 also inhibits TNF-alpha-induced IL-8 expression through this pathway.
MMP upregulation and extracellular matrix remodeling: Tβ4 increases expression of matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, in wound tissue. MMPs degrade the basement membrane and extracellular matrix components that physically block cell migration into the wound bed. This matrix remodeling function is essential for the ingrowth of repair cells and is one mechanism by which Tβ4/TB-500 facilitates rapid wound closure.
Myofibroblast suppression and scar reduction: Tβ4 prevents the appearance of myofibroblasts — the cells responsible for fibrotic scar formation — at healing wound sites. By suppressing myofibroblast differentiation while promoting organized collagen deposition aligned along stress vectors, Tβ4/TB-500 shifts repair outcomes toward regeneration with mature organized connective tissue rather than disorganized fibrotic scarring.
Cardiac Progenitor Cell Activation — The Most Distinctive Application
One of the most scientifically significant and clinically relevant findings in Tβ4 biology is its ability to activate dormant epicardial progenitor cells in the adult heart. The adult mammalian heart has minimal capacity for self-repair following myocardial infarction — the lost cardiomyocytes are replaced primarily by scar tissue rather than new functional muscle. However, the epicardium — the outermost layer of the heart wall — contains progenitor cells that, during embryonic development, give rise to cardiomyocytes and the coronary vasculature.
In the adult heart, these epicardial progenitor cells are quiescent. Tβ4 reactivates them — stimulating their re-entry into the cell cycle, their migration into damaged myocardium, and their differentiation into cardiomyocytes and vascular cells. Bock-Marquette et al. (2010, PMID 20536454) directly demonstrated that Tβ4 is the first known molecule able to initiate simultaneous myocardial and vascular regeneration after systemic administration in vivo — through reactivation of this dormant epicardial progenitor program. This positions Tβ4 as a unique agent at the interface of regenerative medicine and endogenous repair biology, operating through a mechanism unavailable to conventional cardioprotective drugs.
Published Research
Study 1 — Foundational Wound Healing: Thymosin Beta-4 Accelerates Wound Healing in Rat Full-Thickness Wound Model
Authors: Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK (NIH) Year: 1999 Journal: Journal of Investigative Dermatology PMID: 10469335 Full text: https://pubmed.ncbi.nlm.nih.gov/10469335/
This NIH study was the foundational experimental demonstration that Tβ4 accelerates wound healing in an in vivo full-thickness wound model — establishing the wound healing evidence base that drove all subsequent clinical development.
Tβ4 administered topically or intraperitoneally to rats with full-thickness wounds increased reepithelialization by 42% over saline controls at 4 days post-wounding, and by as much as 61% at 7 days. Treated wounds contracted at least 11% more than controls by day 7. Increased collagen deposition and angiogenesis were observed in treated wounds versus controls.
The Boyden chamber assay demonstrated that Tβ4 stimulated keratinocyte migration 2-3 fold over controls — with significant activity at concentrations as low as 10 picograms per milliliter — establishing extraordinary potency of the migration-promoting effect.
These findings directly established Tβ4 as a potent multi-mechanism wound healing factor: simultaneously promoting reepithelialization (keratinocyte migration), wound contraction, collagen deposition, and angiogenesis — four independent components of the wound repair cascade.
Study 2 — Fragment Validation: LKKTETQ Heptapeptide Promotes Repair in Diabetic and Aged Mice
Authors: Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK (NIH) Year: 2003 Journal: Wound Repair and Regeneration PMID: 12581423 Full text: https://pubmed.ncbi.nlm.nih.gov/12581423/
This study is the direct pharmacological validation for TB-500 as an independent research compound — demonstrating that the seven-amino acid synthetic peptide LKKTETQ (the TB-500 sequence, without N-terminal acetylation in this study) reproduces full Tβ4’s wound healing activity.
In db/db diabetic mice, where wound healing is severely impaired due to poor vascular function and cellular repair capacity, Tβ4 significantly increased wound contracture and collagen deposition. Both PBS and hydrogel Tβ4 formulations were active, establishing formulation flexibility for wound delivery.
In 26-month-old aged mice — where healing is significantly delayed due to reduced angiogenesis and cellular migration capacity — Tβ4 accelerated wound healing with increases in keratinocyte migration, wound contracture, and collagen deposition comparable to those seen in younger animals.
The critical direct validation: the actin-binding domain of Tβ4, reproduced in a seven-amino acid synthetic peptide (LKKTETQ), was able to promote repair in the aged animals comparable to that observed with the full 43-amino acid parent molecule. This established pharmacophoric sufficiency of the LKKTETQ sequence and validated TB-500 as a legitimate research fragment rather than merely an untested truncation.
Study 3 — Cardiac Mechanism: ILK Activation and Cardiac Progenitor Migration
Authors: Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D Year: 2004 Journal: Nature PMID: 15565145 (Nature 2004;432(7016):466-472)
This Nature paper was the landmark study establishing Tβ4’s cardiac repair mechanism through ILK activation — one of the most impactful publications in Tβ4 biology and the primary driver of the cardiac clinical development program.
Systemic administration of Tβ4 after experimental myocardial infarction in mice resulted in improved cardiac function, reduced scar size, and enhanced neovascularization. These functional and structural improvements were directly mechanistically attributed to ILK activation.
Tβ4 was shown to form a functional complex with PINCH and ILK — activating ILK, which phosphorylates and activates Akt (protein kinase B). This ILK/Akt activation promotes cardiomyocyte survival (anti-apoptotic), enhances cardiac cell migration to injury sites, and drives cardiac progenitor cell differentiation and incorporation into the repair zone.
Critically, Tβ4 also promoted survival of cardiomyocytes exposed to ischemic conditions in vitro — establishing direct anti-apoptotic cardioprotection independent of its progenitor-mobilizing effects.
The identification of ILK as Tβ4’s cardiac effector kinase established a new mechanistic framework for Tβ4 in cardiac biology: not merely a pro-angiogenic factor, but a direct cardioprotective and cardiac progenitor-activating agent — the first molecule shown to activate the ILK pathway in the context of cardiac repair in this comprehensive manner.
Study 4 — RGN-259 Phase 2: Full Tβ4 in Moderate to Severe Dry Eye
Authors: Sosne G, Ousler GW, et al. (Phase 2 CAE model trial; RegeneRx/ReGenTree) Year: 2015 Journal: Clinical Ophthalmology PMID: 26056426 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC4445951/
This randomized double-blind placebo-controlled Phase 2 study of RGN-259 (0.1% full Tβ4 ophthalmic solution) in 72 subjects with moderate-to-severe dry eye using the controlled adverse environment (CAE) model represents the most methodologically rigorous completed human efficacy trial in the Tβ4/TB-500 research program.
Central corneal fluorescein staining — a primary measure of corneal epithelial integrity — was significantly reduced in Tβ4-treated subjects compared to placebo at the 24-hour follow-up after CAE challenge (P equal to 0.0075). Superior corneal staining showed statistically significant reduction with Tβ4 at an earlier timepoint (P equal to 0.021). These staining results reflect faster corneal epithelial healing in Tβ4-treated eyes.
The mechanism is directly attributable to Tβ4’s LKKTETQ-mediated enhancement of corneal epithelial cell migration — the same cytoskeletal dynamics mechanism that drives dermal wound healing — applied to the rapid resurfacing of the corneal epithelium following environmental desiccation challenge.
RGN-259 was safe and well-tolerated. No significant adverse events were reported. Topical 0.1% Tβ4 ophthalmic solution produced no irritation, no systemic effects, and no safety signals — consistent with the broad tissue tolerance documented across the Tβ4 research literature.
Note: This trial used full 43-amino acid Tβ4 (as RGN-259), not the TB-500 fragment. Results characterize full Tβ4 ophthalmic biology; direct human evidence for the isolated TB-500 fragment does not exist.
Study 5 — Severe Dry Eye and GVHD: Human Clinical Evidence
Authors: Sosne G, Rimmer D, Kleinman HK, Ousler G Year: 2015/2016 Journal: Vitamins and Hormones (review); and Phase 2 clinical trial PMID: 25826322
This Phase 2 multicenter randomized double-blind placebo-controlled 56-day study in nine patients with severe dry eye (including graft-versus-host disease cases — a particularly challenging population) evaluated RGN-259 eye drops.
At day 56 — 28 days after cessation of treatment — the RGN-259-treated group showed 35.1% reduction in ocular discomfort compared with vehicle control (P equal to 0.0141), and 59.1% reduction in total corneal fluorescein staining (P equal to 0.0108). These statistically significant improvements in both symptom and sign measures persisted after treatment cessation — consistent with the durability of epithelial healing rather than a temporary masking effect.
Additional improvements included tear film breakup time and increased tear volume production. The treatment was safe and well-tolerated across the 56-day study period with no serious adverse events.
Study 6 — Cardiac Progenitor Activation and Dual Myocardial-Vascular Regeneration
Authors: Bock-Marquette I et al. Year: 2010 Journal: Published references PMID: 20536454 and related publications
This study identified Tβ4 as the first known molecule able to initiate simultaneous myocardial and vascular regeneration after systemic administration in vivo — through reactivation of dormant epicardial progenitor cells.
Systemic Tβ4 injection stimulated epicardial thickening accompanied by increases in myocardial and epicardial progenitor cell populations, both with and without myocardial infarction — demonstrating that the reactivation of epicardial progenitors is not injury-dependent but can be initiated pharmacologically.
Reactivated epicardial progenitor cells differentiated into cardiomyocytes and contributed to coronary vasculature — establishing that Tβ4 reactivates the full embryonic cardiac developmental program in the adult heart, enabling both muscular and vascular regeneration from a single endogenous progenitor population.
This dual myocardial-vascular regenerative capacity is mechanistically distinct from all prior cardiac repair approaches, which addressed either muscle loss (cell therapy with cardiomyocyte transplantation) or vascular supply (angiogenic therapies) but not both simultaneously.
TB-500 vs Full Thymosin Beta-4 — The Essential Distinction for Research Integrity
This distinction must be clearly stated in any TB-500 research overview because it is consistently misrepresented in non-scientific contexts:
Thymosin Beta-4 (full Tβ4, 43 amino acids): The endogenous naturally occurring peptide. All human clinical trial data — including the RGN-259 dry eye trials, RGN-352 cardiac trial, and RGN-137 dermal wound trial — was generated with full-length Tβ4. Results from these human studies cannot be directly attributed to the TB-500 fragment without direct comparative testing.
TB-500 (Ac-LKKTETQ, 7 amino acids): The synthetic research fragment corresponding to the actin-binding domain. Validated to reproduce the actin sequestration activity of full Tβ4 and to produce wound healing comparable to full Tβ4 in the aged mouse model (Philp 2003). However, it lacks the full C-terminal domain (residues 24-43) which contributes to some of Tβ4’s receptor interactions, nuclear localization, and the full magnitude of ILK/Akt signaling. TB-500 has not been directly tested in human clinical trials.
The correct research interpretation: TB-500 is a validated pharmacological tool for studying Tβ4’s actin-binding biology. Its effects in preclinical models provide meaningful mechanistic data. The human clinical evidence, however, belongs to full-length Tβ4 and should not be attributed to TB-500 specifically.
2024 Finding — Ac-LKKTE Metabolite
A 2024 study identified that the Ac-LKKTE metabolite (a shorter form derived from TB-500’s LKKTETQ sequence) shows increased wound healing activity compared to TB-500 itself in wound healing assays — suggesting that previously reported wound healing effects attributed to TB-500 may derive at least partially from this metabolite rather than the parent compound. This finding adds complexity to the pharmacological interpretation of TB-500’s in vivo effects and represents an active area of investigation.
Current Research Status
Clinical development of full Tβ4 continues through RegeneRx Pharmaceuticals and affiliated licensees, with ongoing interest in ophthalmic (dry eye, neurotrophic keratopathy), cardiac (post-myocardial infarction), and dermal (chronic wound) applications. No FDA approval has been granted for any Tβ4 formulation as of this compilation. TB-500 as a research fragment continues to be used in preclinical studies investigating cytoskeletal dynamics, wound healing mechanisms, cardiac progenitor biology, neurological repair, and angiogenesis. The compound is prohibited in equine sports competition; WADA status for human athletics should be verified for any sports science research application.
Reconstitution Note
TB-500 is supplied as lyophilized powder. Bacteriostatic water is the standard reconstitution solvent. TB-500 dissolves readily in aqueous solution. Protect from light. Avoid repeated freeze-thaw cycles of reconstituted solution. Always confirm the recommended solvent and concentration against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light. Avoid repeated freeze-thaw cycles. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of degradation.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the TB-500 product page: https://roguecompounds.com/product/tb-500/